Although it has been reported that over-expression of p53 resulted in poor survival in HCC 33, the inconsistency in the present study might be due to the different inclusion criteria and clinical management with sorafenib for HCC patients nowadays. The gene discussed is TP53; the disease is hepatocellular carcinoma.